A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.

Start Date15 Jul 2021

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

[+1]

100 Clinical Results associated with Personalized vaccine(Beijing Neoantigen Biotechnology Company)

100 Translational Medicine associated with Personalized vaccine(Beijing Neoantigen Biotechnology Company)

100 Patents (Medical) associated with Personalized vaccine(Beijing Neoantigen Biotechnology Company)

Literatures (Medical) associated with Personalized vaccine(Beijing Neoantigen Biotechnology Company)

01 Feb 2023·Cancer Immunology, Immunotherapy

Personalized tumor vaccine for pancreatic cancer

Article

Author: Liegel, Jessica ; Muthuswamy, Senthil K ; Kufe, Donald ; Torres, Daniela ; Stroopinsky, Dina ; Hidalgo, Manuel ; Tacettin, Cansu ; Cheloni, Giulia ; Huang, Ling ; Ephraim, Adam ; Gandarilla, Omar ; Avigan, David ; Orr, Shira ; Rosenblatt, Jacalyn ; DeCicco, Cori ; Moser, James

BACKGROUNDPancreatic cancer is a highly lethal malignancy often presenting with advanced disease and characterized by resistance to standard chemotherapy. Immune-based therapies such checkpoint inhibition have been largely ineffective such that pancreatic cancer is categorized as an immunologically "cold tumor". In the present study, we examine the therapeutic efficacy of a personalized cancer vaccine in which tumor cells are fused with dendritic cells (DC) resulting in the broad induction of antitumor immunity.RESULTSIn the KPC spontaneous pancreatic cancer murine model, we demonstrated that vaccination with DC/KPC fusions led to expansion of pancreatic cancer specific lymphocytes with an activated phenotype. Remarkably, vaccination led to a reduction in tumor bulk and near doubling of median survival in this highly aggressive model. In a second murine pancreatic model (Panc02), vaccination with DC/tumor fusions similarly led to expansion of tumor antigen specific lymphocytes and their infiltration to the tumor site. Having shown efficacy in immunocompetent murine models, we subsequently demonstrated that DC/tumor fusions generated from primary human pancreatic cancer and autologous DCs potently stimulate tumor specific cytotoxic lymphocyte responses.CONCLUSIONSDC/tumor fusions induce the activation and expansion of tumor reactive lymphocytes with the capacity to infiltrate into the pancreatic cancer tumor bed.

14 Apr 2017·ScienceQ1 · CROSS-FIELD

Personalized tumor vaccines keep cancer in check

Q1 · CROSS-FIELD

Article

Author: Kaiser, Jocelyn

A new approach enlists a tumor's own mutated proteins.

100 Deals associated with Personalized vaccine(Beijing Neoantigen Biotechnology Company)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Glioma	Phase 1	CN	Xuanwu Hospital Capital Medical University	15 Jul 2021
Recurrent Malignant Glioma	Phase 1	CN	Xuanwu Hospital Capital Medical University	15 Jul 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Personalized vaccine(Beijing Neoantigen Biotechnology Company)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation